Table 2:
Distribution of clinical characteristics in SAMS group and statin-tolerant group
| Characteristic N (%) |
SAMS Group (n=634) |
Statin-Tolerant Group (n=114) |
P-value* |
|---|---|---|---|
| Family history of heart disease | 341 (53.8) | 22 (19.3) | 0.0001 |
| Hypertension | 322 (50.8) | 27 (23.7) | 0.0001 |
| History of smoking | 239 (37.7) | 18 (15.8) | 0.0001 |
| Obesity | 127 (20.0) | 5 (4.4) | 0.0001 |
| Coronary artery disease | 136 (21.5) | 8 (7.0) | 0.0003 |
| Inflammatory muscle disease | 57 (9.0) | 0 (0.0) | 0.001 |
| Cognitive impairment | 33 (5) | NA | |
| Persistent symptoms ≥6 months | 226 (36) | NA | |
| Progressive course | 234 (37) | NA | |
| CK >4XULN (only 40% had CK measured in test group; 253/634) | 144/253 (57) | 1 | |
| Hypothyroidism | 89 (14.0) | 6 (5.3) | 0.01 |
| Metabolic muscle disease | 19 (3.0) | 0 (0.0) | 0.06 |
| Previous heart attack | 91 (14.4) | 9 (7.9) | 0.06 |
| Heavy alcohol consumption | 17 (2.7) | 0 (0.0) | 0.08 |
| Liver disease | 17 (2.7) | 0 (0.0) | 0.08 |
| Diabetes | 103 (16.3) | 12 (10.5) | 0.12 |
| Family history of muscle disease | 39 (6.2) | 4 (3.5) | 0.26 |
| Renal disease | 15 (2.4) | 1 (0.9) | 0.31 |
*
P-values denote results chi-square tests.
NA, not reported in statin-tolerant group.
SAMS: statin-associated muscle symptoms; CK: creatine kinase